Form 8-K/A - Current report: [Amend]
SEC Accession No. 0000950170-25-058837
Filing Date
2025-04-25
Accepted
2025-04-25 16:56:58
Documents
11
Period of Report
2025-01-29
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K/A jagx-20250129.htm   iXBRL 8-K/A 53543
  Complete submission text file 0000950170-25-058837.txt   173932

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT jagx-20250129.xsd EX-101.SCH 25825
13 EXTRACTED XBRL INSTANCE DOCUMENT jagx-20250129_htm.xml XML 5687
Mailing Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104
Business Address 200 PINE STREET SUITE 400 SAN FRANCISCO CA 94104 415-371-8300
Jaguar Health, Inc. (Filer) CIK: 0001585608 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-36714 | Film No.: 25875001
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)